Navigation Links
Today's Research on Mylan and Watson Pharmaceuticals: One Drug Maker's Sorrow is Another One's Joy
Date:1/18/2013

LONDON, January 18, 2013 /PRNewswire/ --

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers in the past years and this trend is expected to go for some years to come. In 2012 alone, over 40 branded drugs with a $35 billion yearly sales tag have lost patent protection. StockCall has technical coverage on two of the biggest generic makers, Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is available for free upon registration at http://www.stockcall.com/report    

The generic drug industry has been feasting on patent expirations in recent years, and if the start of 2013 is anything to go on, this year could see more of the same. Major branded drug companies have lost exclusivity rights to a number of top selling products, and generic alternatives, as well as customer's pockets, have been the main beneficiaries.

Mylan only recently announced that it is now releasing its generic of Pfizer's Dilantin tablets after receiving the FDA's seal of approval. Dilantin is given for the control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e., psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring during or following neurosurgery. According to IMS Health, the 50 mg chewable tablet saw U.S. sales of close to $16.5 million for a 12 month period ending September 30, 2012. See our technical analysis on Mylan by sign up now at http://www.StockCall.com/MYL011813.pdf

Also in news lately has been Watson Pharmaceuticals Inc.'s [Free Analysis Report on WPI] [(1)] generic version of Ferring Pharmaceuticals' Lysteda tablet which received the FDA's approval even as an infringement lawsuit against Watson Pharma has been filed by the original maker of the drug. Whilst this legal battle is still pending, Watson Pharma intends to make the most of the time to launch its generic version. Last year, Lysteda saw revenues of close to $25 million in the U.S.

Generic companies also currently have an impressive list of abbreviated new drug applications awaiting FDA approval. Those that have first-to-file status have the potential to be even more lucrative as these companies can enjoy a period of generic exclusivity that is usually 180 days.  

Select generic drug makers have been focusing on expansion of late, in an attempt to grow sales and profits. Some have been acquiring competitors, while others have been investing in growing their presence abroad. Regardless, generic drug companies appear to be in a strong position to grow in 2013.

Footer:

  1. Watson Pharmaceuticals Inc. Technical Analysis [ http://www.StockCall.com/WatsonPharmaceuticalsInc011813.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
2. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
3. Notre Dame to be part of $194 million university research center network
4. Researchers create method for more sensitive electrochemical sensors
5. Global Soil Treatment Market Forecast to Grow at a CAGR of 8.5% to 2017 in New Research Report at ReportsnReports.com
6. Global Healthcare Contract Research Outsourcing Market is expected to reach USD 65.03 billion by 2018: Transparency Market Research
7. Nanofiber Production Device Set to Accelerate Research into Nanofiber Applications in Medicine
8. CIS MDI (Methyl Diphenyl Diisocyanate) Market - New Industry Research Report Published by Transparency Market Research
9. Butanes Market - New Industry Research Report Published by Transparency Market Research
10. New research gives insight into graphene grain boundaries
11. Sustainable Valley Technology Group Provides Technology Innovation Grant To Help Researchers & Start-Ups With Funding, Business Support, Equipment & Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):